Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Gabriel Abril-Rodriguez^{1

2}, Davis Y Torrejon¹, Wei Liu^{3

4}, Jesse M Zaretsky¹, Theodore S Nowicki⁵, Jennifer Tsoi¹, Cristina Puig-Saus¹, Ignacio Baselga-Carretero¹, Egmidio Medina¹, Michael J Quist¹, Alejandro J Garcia¹, William Senapedis⁶, Erkan Baloglu⁶, Anusha Kalbasi^{7

8

9}, Gardenia Cheung-Lau¹, Beata Berent-Maoz¹, Begoña Comin-Anduix^{8

9}, Siwen Hu-Lieskovan^{1

9}, Cun-Yu Wang^{3

4}, Catherine S Grasso^#¹, Antoni Ribas^#^{10

11

12

13

14}

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
² Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
³ Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
⁴ Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.
⁵ Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA.
⁶ Karyopharm Therapeutics, Newton, MA, USA.
⁷ Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
⁸ Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
⁹ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
¹⁰ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹¹ Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹² Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹³ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. aribas@mednet.ucla.edu.

^# Contributed equally.

PMID: 35122015
DOI: 10.1038/s43018-020-0025-7

Free article

Published Erratum

Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Gabriel Abril-Rodriguez et al. Nat Cancer. 2020 Feb.

Free article

. 2020 Feb;1(2):264.

doi: 10.1038/s43018-020-0025-7.

Authors

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
² Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
³ Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
⁴ Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.
⁵ Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA.
⁶ Karyopharm Therapeutics, Newton, MA, USA.
⁷ Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
⁸ Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
⁹ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
¹⁰ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹¹ Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹² Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹³ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
¹⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. aribas@mednet.ucla.edu.

^# Contributed equally.

PMID: 35122015
DOI: 10.1038/s43018-020-0025-7

No abstract available

PubMed Disclaimer

Erratum for

PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Nat Cancer. 2020;1(1):46-58. doi: 10.1038/s43018-019-0003-0. Epub 2019 Dec 9. Nat Cancer. 2020. PMID: 34368780 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- eScholarship, University of California - Access Free Full Text
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Affiliations

Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials